Next Article in Journal
Validation and Application of Skin RT-QuIC to Patients in China with Probable CJD
Next Article in Special Issue
First Detection and Genomic Characterization of Bovine Norovirus from Yak
Previous Article in Journal
Genotyping and Antimicrobial Susceptibility of Clostridium perfringens and Clostridioides difficile in Camel Minced Meat
Previous Article in Special Issue
Assessment of Food and Waterborne Viral Outbreaks by Using Field Epidemiologic, Modern Laboratory and Statistical Methods—Lessons Learnt from Seven Major Norovirus Outbreaks in Finland
Review

Norovirus Vaccines: Current Clinical Development and Challenges

by 1,2
1
Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
2
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
Academic Editor: Carl Kirkwood
Pathogens 2021, 10(12), 1641; https://doi.org/10.3390/pathogens10121641
Received: 21 November 2021 / Revised: 14 December 2021 / Accepted: 16 December 2021 / Published: 19 December 2021
(This article belongs to the Special Issue Norovirus and Viral Gastroenteritis)
Noroviruses are the major viral pathogens causing epidemic and endemic acute gastroenteritis with significant morbidity and mortality. While vaccines against norovirus diseases have been shown to be of high significance, the development of a broadly effective norovirus vaccine remains difficult, owing to the wide genetic and antigenic diversity of noroviruses with multiple co-circulated variants of various genotypes. In addition, the absence of a robust cell culture system, an efficient animal model, and reliable immune markers of norovirus protection for vaccine evaluation further hinders the developmental process. Among the vaccine candidates that are currently under clinical studies, recombinant VP1-based virus-like particles (VLPs) that mimic major antigenic features of noroviruses are the common ones, with proven safety, immunogenicity, and protective efficacy, supporting a high success likelihood of a useful norovirus vaccine. This short article reviews the recent progress in norovirus vaccine development, focusing on those from recent clinical studies, as well as summarizes the barriers that are being encountered in this developmental process and discusses issues of future perspective. View Full-Text
Keywords: norovirus; gastroenteritis; vaccine; immunogenicity; antiviral norovirus; gastroenteritis; vaccine; immunogenicity; antiviral
MDPI and ACS Style

Tan, M. Norovirus Vaccines: Current Clinical Development and Challenges. Pathogens 2021, 10, 1641. https://doi.org/10.3390/pathogens10121641

AMA Style

Tan M. Norovirus Vaccines: Current Clinical Development and Challenges. Pathogens. 2021; 10(12):1641. https://doi.org/10.3390/pathogens10121641

Chicago/Turabian Style

Tan, Ming. 2021. "Norovirus Vaccines: Current Clinical Development and Challenges" Pathogens 10, no. 12: 1641. https://doi.org/10.3390/pathogens10121641

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop